Literature DB >> 31319038

Associations of P2RX7 Functional Diplotypes with Localized Aggressive Periodontitis.

T H Harris1,2, M R Wallace3,4, H Huang1, H Li3, L M Shaddox1,5.   

Abstract

AIM: The purpose of this study was to test for the role of the P2X7 receptor in localized aggressive periodontitis (LAP).
METHODS: Peripheral blood was obtained from 95 subjects with LAP and 76 healthy unrelated controls (HUCs). Three P2RX7 single-nucleotide polymorphisms (rs1718119, rs2230911, and rs3751143) were genotyped from these subjects, and their peripheral blood samples were stimulated with lipopolysaccharide (LPS) from Escherichia coli and tested for inflammatory markers. The 3 P2RX7 single-nucleotide polymorphisms were in found to be in perfect linkage disequilibrium, and a total of 4 haplotypes and 9 diplotypes were identified among all subjects. For both subject populations, the 9 diplotypes were grouped into 4 functional groups and tested for association with subject inflammatory response. To specifically study the effects of extrinsic activation of the P2X7 receptor in LAP, peripheral blood samples from were stimulated under 3 treatments: LPS, LPS + ATP, and LPS +ATP+ P2X7 selective inhibitor. The effects of these treatments on P2X7 receptor activity were measured through Luminex protein assay. Last, to test whether receptor stimulation was related to P2RX7 expression, relative mRNA levels of P2RX7 were quantified with real-time quantitative polymerase chain reaction.
RESULTS: Several associations between the P2RX7 diplotypes and LPS-stimulated blood chemokine/cytokine levels were found between the LAP and HUC populations (P < 0.05). P2X7 activation resulted in statistically significant differences in IL-1β and IL-12p40 concentrations for both subject populations. The relative P2RX7 mRNA levels increased significantly after addition of its inhibitor for both LAP and HUC populations.
CONCLUSIONS: This study detected an association between P2RX7 functional diplotypes and in vitro immune response of whole blood from subjects with LAP. In addition, we found that inhibition of the activated P2X7 receptor leads to increased P2RX7 mRNA levels, suggesting a feedback loop ( ClinicalTrials.gov NCT01330719). KNOWLEDGE TRANSFER STATEMENT: The results of this study suggest that P2RX7 functional diplotypes are associated with LAP and their in vitro immune response to bacteria. Ongoing studies to uncover the mechanistic link between P2RX7 and LAP phenotypes could lead to the development of preventive approaches for susceptible subjects.

Entities:  

Keywords:  cytokine(s); genetics; inflammation; molecular genetics; periodontal diseases; single nucleotide polymorphism

Mesh:

Year:  2019        PMID: 31319038      PMCID: PMC6749795          DOI: 10.1177/2380084419863789

Source DB:  PubMed          Journal:  JDR Clin Trans Res        ISSN: 2380-0844


  42 in total

1.  Mitochondrial Dysfunction, Depleted Purinergic Signaling, and Defective T Cell Vigilance and Immune Defense.

Authors:  Carola Ledderose; Yi Bao; Stephan Ledderose; Tobias Woehrle; Maria Heinisch; Linda Yip; Jingping Zhang; Simon C Robson; Nathan I Shapiro; Wolfgang G Junger
Journal:  J Infect Dis       Date:  2015-07-06       Impact factor: 5.226

2.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  Int J Surg       Date:  2014-07-18       Impact factor: 6.071

3.  Association of P2RX7 functional variants with localized aggressive periodontitis.

Authors:  Theodore H Harris; Margaret R Wallace; Hong Huang; Hua Li; Azeem Mohiuddeen; Yan Gong; Theodora Kompotiati; Peter Harrison; Ikramuddin Aukhil; Luciana M Shaddox
Journal:  J Periodontal Res       Date:  2019-07-10       Impact factor: 4.419

Review 4.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

5.  Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

Authors:  Panos N Papapanou; Mariano Sanz; Nurcan Buduneli; Thomas Dietrich; Magda Feres; Daniel H Fine; Thomas F Flemmig; Raul Garcia; William V Giannobile; Filippo Graziani; Henry Greenwell; David Herrera; Richard T Kao; Moritz Kebschull; Denis F Kinane; Keith L Kirkwood; Thomas Kocher; Kenneth S Kornman; Purnima S Kumar; Bruno G Loos; Eli Machtei; Huanxin Meng; Andrea Mombelli; Ian Needleman; Steven Offenbacher; Gregory J Seymour; Ricardo Teles; Maurizio S Tonetti
Journal:  J Clin Periodontol       Date:  2018-06       Impact factor: 8.728

6.  Extracellular adenosine 5'-triphosphate and lipopolysaccharide induce interleukin-1β release in canine blood.

Authors:  Mari Spildrejorde; Stephen J Curtis; Belinda L Curtis; Ronald Sluyter
Journal:  Vet Immunol Immunopathol       Date:  2013-11-08       Impact factor: 2.046

7.  Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes.

Authors:  Ronald Sluyter; Anne N Shemon; James S Wiley
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

8.  Hyper-responsive phenotype in localized aggressive periodontitis.

Authors:  L Shaddox; J Wiedey; E Bimstein; I Magnuson; M Clare-Salzler; I Aukhil; S M Wallet
Journal:  J Dent Res       Date:  2009-12-30       Impact factor: 6.116

Review 9.  The P2X7 Receptor.

Authors:  Ronald Sluyter
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

10.  A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events.

Authors:  Olof Gidlöf; J Gustav Smith; Olle Melander; Håkan Lövkvist; Bo Hedblad; Gunnar Engström; Peter Nilsson; Joyce Carlson; Göran Berglund; Sandra Olsson; Katarina Jood; Christina Jern; Bo Norrving; Arne Lindgren; David Erlinge
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.